Bio Green Med Solution, Inc.
BGMSNasdaq
$0.95
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↓ -88.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.2M
Enterprise Value
$1.8M
P/E
—
P/S
—
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$3.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-46.1%
ROIC
-103.0%
Debt / Equity
—
Net Cash
$3.3M
Return 1Y
-88.5%
Company profile
Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.
- CEO
- Spiro Rombotis
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 14
- Headquarters
- New Jersey
- Website
- cyclacel.com
Management & directors
- Doris Wong Sing EeChief Executive Officer
- Kiu Cu SengChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
BGMS Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$743,000.00—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $420,000.00 | $43,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.6M | -$22.4M | -$27.7M | -$25.5M | -$12.0M | -$8.4M |
| Net income | -$8.4M | -$18.5M | -$21.2M | $22.6M | -$11.2M | -$3.0M |
| Diluted EPS | -$3.42 | -$2.09 | -$27.24 | -$6,419.18 | -$502.46 | -$6.45 |
| Operating cash flow | -$7.9M | -$18.5M | -$20.8M | -$16.1M | -$8.0M | -$4.8M |
| Free cash flow | -$8.0M | -$18.6M | -$20.8M | -$16.1M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -6060.2% | -27916.3% | — |
| Net margin | — | — | — | 5370.2% | -26074.4% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4,000.00 | $10,000.00 | $0.00 | — | — | $81,000.00 | — | $743,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.6M | -$2.2M | -$1.8M | -$4.2M | -$1.3M | -$992,000.00 | -$1.9M | -$246,000.00 |
| Net income | -$3.3M | -$2.0M | -$3.1M | -$81,000.00 | -$1.3M | -$988,000.00 | -$611,000.00 | -$197,000.00 |
| Diluted EPS | -$172.18 | -$43.80 | -$284.21 | $0.00 | -$0.98 | -$1.31 | -$4.16 | — |
| Operating cash flow | -$3.1M | -$3.1M | -$1.4M | -$3.2M | -$1.1M | -$434,000.00 | -$33,000.00 | -$278,000.00 |
| Free cash flow | — | -$3.1M | — | — | — | — | — | -$279,000.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -91100.0% | -21770.0% | — | — | — | -1224.7% | — | -33.1% |
| Net margin | -81425.0% | -19570.0% | — | — | — | -1219.8% | — | -26.5% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-12 | Doris Wong Sing Ee· Chief Executive Officer | Award | 300,178 | $1.40 | $420,249.20 | filing |
| 2025-11-12 | Kiu Cu Seng· Chief Financial Officer | Award | 200,000 | $1.40 | $280,000.00 | filing |
| 2025-11-05 | Yap Kim Choy | Sale | 28,540 | $1.70 | $48,518.00 | filing |
| 2025-11-05 | Yap Kim Choy | J | 467,535 | $0.00 | $0.00 | filing |
| 2025-11-05 | Ong Yee Lung | J | 467,535 | $0.00 | $0.00 | filing |
| 2025-11-05 | Kua Khai Loon | J | 467,535 | $0.00 | $0.00 | filing |
| 2025-10-30 | Ong Yee Lung | Sale | 248,814 | $1.80 | $447,865.20 | filing |
| 2025-10-30 | Kua Khai Loon | Sale | 242,477 | $1.80 | $436,458.60 | filing |
| 2025-10-30 | Yap Kim Choy | Sale | 112,260 | $1.81 | $202,853.82 | filing |
| 2025-10-29 | Yap Kim Choy | Sale | 110,749 | $1.83 | $203,113.67 | filing |
| 2025-10-28 | Yap Kim Choy | Sale | 13,111 | $1.83 | $23,966.91 | filing |
| 2025-10-27 | Yap Kim Choy | Sale | 120,250 | $2.12 | $254,689.50 | filing |
| 2025-10-24 | Ong Yee Lung | Sale | 19,858 | $1.99 | $39,517.42 | filing |
| 2025-10-24 | Yap Kim Choy | Sale | 19,595 | $1.90 | $37,269.69 | filing |
| 2025-10-21 | FITTERS Diversified Berhad | Sale | 92,352 | $3.01 | $277,517.76 | filing |
| 2025-10-20 | FITTERS Diversified Berhad | Sale | 108,107 | $3.09 | $333,834.42 | filing |
| 2025-10-16 | Kua Khai Loon | Sale | 88,204 | $4.22 | $371,956.27 | filing |
| 2025-10-16 | FITTERS Diversified Berhad | Sale | 26,051 | $5.50 | $143,280.50 | filing |
| 2025-10-15 | Kua Khai Loon | Sale | 7,479 | $5.66 | $42,338.62 | filing |
| 2025-10-14 | Ong Yee Lung | Sale | 135,793 | $6.00 | $814,758.00 | filing |
| 2025-10-10 | FITTERS Diversified Berhad | Sale | 51,400 | $5.26 | $270,261.20 | filing |
| 2025-10-08 | FITTERS Diversified Berhad | Sale | 142,000 | $5.29 | $751,606.00 | filing |
| 2025-09-16 | Kua Khai Loon | Sale | 25,000 | $5.13 | $128,300.00 | filing |
| 2025-09-12 | Kua Khai Loon | Sale | 22,251 | $6.22 | $138,490.22 | filing |
| 2025-09-05 | Kua Khai Loon | Sale | 19,054 | $7.01 | $133,568.54 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.